These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 28393419

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Design and Discovery of Novel 1,3,5-Triazines as Dipeptidyl Peptidase-4 Inhibitor against Diabetes.
    Wang Y, Tang X, Yi L.
    Pharmacology; 2019; 103(5-6):273-281. PubMed ID: 30799431
    [Abstract] [Full Text] [Related]

  • 43. Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes.
    Sagar SR, Agarwal JK, Pandya DH, Dash RP, Nivsarkar M, Vasu KK.
    Bioorg Med Chem Lett; 2015 Oct 15; 25(20):4428-33. PubMed ID: 26372650
    [Abstract] [Full Text] [Related]

  • 44. Structure-based virtual screening of dipeptidyl peptidase 4 inhibitors and their in vitro analysis.
    Rahman SU, Ali HS, Jafari B, Zaib S, Hameed A, Al-Kahraman YMSA, Langer P, Iqbal J.
    Comput Biol Chem; 2021 Apr 15; 91():107326. PubMed ID: 32739275
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li Q, Deng X, Jiang N, Meng L, Xing J, Jiang W, Xu Y.
    Eur J Med Chem; 2021 Dec 05; 225():113765. PubMed ID: 34399391
    [Abstract] [Full Text] [Related]

  • 51. Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool.
    Zeng S, Dou W, Li M, Zhou Y, Guo J, Zhao N, Huang H, Zhou Q, Hu W, Ma Y, Zhao X, Xie H.
    ChemMedChem; 2020 Aug 19; 15(16):1608-1617. PubMed ID: 32558296
    [Abstract] [Full Text] [Related]

  • 52. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 Aug 19; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 53. Synthesis, nitric oxide release, and dipeptidyl peptidase-4 inhibition of sitagliptin derivatives as new multifunctional antidiabetic agents.
    Xie Y, Shao L, Wang Q, Bai Y, Chen Z, Li N, Xu Y, Li Y, Yang G, Bian X.
    Bioorg Med Chem Lett; 2018 Dec 15; 28(23-24):3731-3735. PubMed ID: 30343953
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Hypoglycemic peptide-enriched hydrolysates of Corbicula fluminea and Chlorella sorokiniana possess synergistic hypoglycemic activity through inhibiting α-glucosidase and dipeptidyl peptidase-4 activity.
    Huang TH, Liu PY, Lin YL, Tsai JS.
    J Sci Food Agric; 2022 Jan 30; 102(2):716-723. PubMed ID: 34171123
    [Abstract] [Full Text] [Related]

  • 56. A review upon medicinal perspective and designing rationale of DPP-4 inhibitors.
    Kumar S, Mittal A, Mittal A.
    Bioorg Med Chem; 2021 Sep 15; 46():116354. PubMed ID: 34428715
    [Abstract] [Full Text] [Related]

  • 57. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Kushwaha RN, Srivastava R, Mishra A, Rawat AK, Srivastava AK, Haq W, Katti SB.
    Chem Biol Drug Des; 2015 Apr 15; 85(4):439-46. PubMed ID: 25216392
    [Abstract] [Full Text] [Related]

  • 58. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H, Wang YT, Tsai JJ, Chen YC.
    Int J Mol Sci; 2016 Jun 13; 17(6):. PubMed ID: 27304951
    [Abstract] [Full Text] [Related]

  • 59. Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization.
    Zeng S, Xie H, Zeng LL, Lu X, Zhao X, Zhang GC, Tu ZC, Xu HJ, Yang L, Zhang XQ, Hu W.
    Bioorg Med Chem; 2013 Apr 01; 21(7):1749-55. PubMed ID: 23434133
    [Abstract] [Full Text] [Related]

  • 60. Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions.
    Watanabe YS, Yasuda Y, Kojima Y, Okada S, Motoyama T, Takahashi R, Oka M.
    J Enzyme Inhib Med Chem; 2015 Dec 01; 30(6):981-8. PubMed ID: 26147347
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.